Mereo Biopharma Group PLC Form 4 insider transactions

Mereo BioPharma Group plc Director Pierre Jacquet received equity awards, including share options and deferred restricted stock units, as part of his compensation.

Mereo BioPharma Group plc director Marc J Yoskowitz received 66,000 share options and 96,163 deferred restricted stock units.

Mereo BioPharma Group plc Director Daniel Shames acquired 66,000 share options and 96,163 deferred restricted stock units, increasing his beneficial ownership.

Mereo BioPharma Group plc Director Anders Ekblom was granted 66,000 share options and 133,560 deferred restricted stock units.

Mereo BioPharma Group plc Director Jeremy Bender was granted 66,000 share options and 117,533 deferred restricted stock units on February 26, 2026.

Mereo BioPharma Group plc Director Deepika Pakianathan was granted 66,000 share options with an exercise price of $0.39, vesting over one year.

Mereo BioPharma Group plc Director Annalisa Jenkins was granted share options and deferred restricted stock units.

Mereo BioPharma Group plc Director Michael S. Wyzga was granted 66,000 share options with an exercise price of $0.39, vesting over one year.

Mereo BioPharma Group plc's Chief Scientific Officer, John A. Lewicki, was granted 331,550 American Depositary Share options with varying exercise prices and vesting schedules.

Mereo BioPharma's Chief Patient Access and Commercial Planning, Alexandra Hughes-Wilson, was granted a total of 440,000 stock options with varying exercise prices and vesting schedules.

Mereo BioPharma Group plc's General Counsel, Charles Sermon, was granted 716,000 American Depositary Share options with varying exercise prices and vesting schedules.

Mereo BioPharma Group plc's CEO, Denise Scots-Knight, was granted 1,860,000 share options for American Depositary Shares.

Director Marc J. Yoskowitz reports acquisition of share options and deferred restricted stock units in Mereo BioPharma Group plc.

Director Deepika Pakianathan of Mereo BioPharma Group plc was granted 55,000 share options on February 5, 2025, vesting monthly over one year.

Director Jeremy Bender reports acquisition of share options and deferred restricted stock units in Mereo BioPharma Group plc.

Director Anders Ekblom reports acquisition and disposal of derivative securities in Mereo BioPharma Group plc.

Michael S. Wyzga, a director at Mereo BioPharma Group plc, reports acquisition of share options and deferred restricted stock units.

Director Daniel Shames receives stock options and deferred restricted stock units in Mereo BioPharma Group plc.

Annalisa Jenkins, a director of Mereo BioPharma Group plc, reported the acquisition of share options and deferred restricted stock units (DRSUs) on February 5, 2025.

Director Pierre Jacquet reports acquisition and disposal of derivative securities in Mereo BioPharma Group plc.

John A. Lewicki, Chief Scientific Officer of Mereo BioPharma Group plc, acquired 116,000 share options on January 25, 2025.

Christine Ann Fox, CFO of Mereo BioPharma Group plc, reports the acquisition of share options.

Charles Sermon, General Counsel of Mereo BioPharma Group PLC, reports the acquisition of share options on January 25, 2025.

Alexandra Hughes-Wilson, a Mereo BioPharma Group plc officer, was granted share options exercisable for 154,000 American Depository Shares.

Denise Scots-Knight, CEO of Mereo BioPharma Group plc, was granted share options for 825,000 American Depository Shares on January 25, 2025.

Mereo BioPharma Group plc CEO, Denise Scots-Knight, sold American Depositary Shares (ADS) to cover tax withholding obligations related to the vesting of performance-based restricted stock units.

John A. Lewicki, Chief Scientific Officer of Mereo BioPharma Group plc, sold shares to cover tax withholding obligations related to vested restricted stock units.

Charles Sermon, General Counsel of Mereo BioPharma Group plc, sold American Depositary Shares (ADS) to cover tax withholding obligations related to vested restricted stock units.

Christine Ann Fox, CFO of Mereo BioPharma Group plc, sold shares to cover tax withholding obligations related to vested restricted stock units.

Alexandra Hughes-Wilson, a Mereo BioPharma Group plc officer, sold American Depositary Shares (ADS) to cover tax withholding obligations related to vesting of restricted stock units and exercise of stock options.